Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors-Reference-Cited by-同舟云学术

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

Published:2021-01-01 Issue:1 Volume:13 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Wingert Susanne¹,Reusch Uwe¹,Knackmuss Stefan¹,Kluge Michael¹,Damrat Michael¹,Pahl Jens¹,Schniegler-Mattox Ute¹,Mueller Thomas¹,Fucek Ivica¹,Ellwanger Kristina¹,Tesar Michael¹,Haneke Torsten¹^ORCID,Koch Joachim¹,Treder Martin²,Fischer Wolfgang¹,Rajkovic Erich¹

Affiliation:

1. Research & Development, Affimed GmbH, Heidelberg, Germany

2. Formerly Affimed GmbH, Heidelberg, Germany. Now: Arjuna Therapeutics, Santiago De Compostela, Spain

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2021.1950264

Reference59 articles.

1. Review of epidermal growth factor receptor biology

2. Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial